Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|April 21, 2020
- April 2020
- Volume 88
- Issue 4
CE: Emerging Strategies in the Treatment and Management of Idiopathic Pulmonary Fibrosis
This activity is supported by an educational grant from Genentech.
Advertisement
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Explore the pathophysiology and treatment challenges associated with idiopathic pulmonary fibrosis (IPF)
- Examine the safety and efficacy of available therapies for the treatment of IPF
- Identify the role of the specialty pharmacist as patient counselor in the management of IPF
FACULTY
Geoffrey C. Wall, PharmD, BCPS, FCCP
Ellis Professor of Pharmacy Practice, Drake University College of Pharmacy and Health Sciences; Internal Medicine Clinical Pharmacist, Iowa Methodist Medical Center, Des Moines, Iowa
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: April 13, 2020
EXPIRATION DATE: April 13, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
over 6 years ago
Stark Law Aims to Prevent Financial Gain From Self-Referralsover 6 years ago
Competition Lowers Drug Prices, FDA Saysover 6 years ago
Techs’ Role in Immunization Administration Expandsover 6 years ago
Telehealth Offers Myriad Unique Opportunities for Pharmacistsover 6 years ago
High-Alert Medications Require Special Safeguardsover 6 years ago
Brush Up on Mumps and Key Precautionsover 6 years ago
Nasal Polyps Pose Treatment Challengesover 6 years ago
Diversion Occurs in HospiceAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5